Table 2. Effects of n-3 PUFAs on MMP9: Evidence from Clinical Studies.

S/N	Ref	Patients	Main finding
1	[126]	Relapsing-remitting multiple sclerosis patients	EPA and DHA resulted in a significant decrease in MMP9 protein and activity in the PBMCs
2	[127]	Healthy subjects	n-3 PUFAs significantly decreased MMP9 secretion from the PBMCs
3	[128]	Clinical	The activity of MMP9 in the amnion was significantly reduced by treatment with EPA and DHA compared to control
4	[129]	Dry eye disease patients	n-3 PUFAs decrease MMP9 positivity

EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; MMP9, Matrix metalloproteinase 9; n-3 PUFAs, omega-3 polyunsaturated fatty acids; PBMCs, Peripheral blood mononuclear cells.